Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors)
CI Liakos, DP Papadopoulos, EA Sanidas… - American Journal of …, 2021 - Springer
The prevalence of arterial hypertension is high in patients with diabetes mellitus (DM). When
DM and hypertension coexist, they constitute a dual cardiovascular threat and should be …
DM and hypertension coexist, they constitute a dual cardiovascular threat and should be …
Biological context linking hypertension and higher risk for COVID-19 severity
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), represents a public health crisis of major …
syndrome coronavirus 2 (SARS-CoV-2), represents a public health crisis of major …
Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes
S Wakasugi, T Mita, N Katakami, Y Okada… - Cardiovascular …, 2021 - Springer
Background Previous studies have suggested that high mean glucose levels and glycemic
abnormalities such as glucose fluctuation and hypoglycemia accelerate the progression of …
abnormalities such as glucose fluctuation and hypoglycemia accelerate the progression of …
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group …
N Katakami, T Mita, H Yoshii, T Shiraiwa… - Cardiovascular …, 2021 - Springer
Background Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects,
including improved glycemic control and serum lipid profile and decreased body weight …
including improved glycemic control and serum lipid profile and decreased body weight …
A dipeptidyl peptidase-4 inhibitor inhibits foam cell formation of macrophages in type 1 diabetes via suppression of CD36 and ACAT-1 expression
M Terasaki, H Yashima, Y Mori, T Saito… - International Journal of …, 2020 - mdpi.com
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to play a protective role
against atherosclerosis in both animal models and patients with type 2 diabetes (T2D) …
against atherosclerosis in both animal models and patients with type 2 diabetes (T2D) …
Diabetes and seeds: New horizon to promote human nutrition and anti-diabetics compounds in grains by germination
ABSTRACT Type 2 diabetes (T2D) is a complex and heterogeneous chronic metabolic
disorder disease that is associated with high blood sugar. Because of the side effects of …
disorder disease that is associated with high blood sugar. Because of the side effects of …
Association of retinol binding protein-4 (RBP4) with glycemia, dyslipidemia, hypertension, and obesity in type 2 diabetic Iraqi patients
Background: Retinol binding protein 4 (RBP4), an adipokine that participate in a lipid
metabolism or insulin resistance through a complex regulatory network. Recently, RBP4 was …
metabolism or insulin resistance through a complex regulatory network. Recently, RBP4 was …
DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice
R Nistala, AI Meuth, C Smith, J An… - American Journal …, 2021 - journals.physiology.org
Recent evidence suggests that dipeptidyl peptidase-4 (DPP4) inhibition with saxagliptin
(Saxa) is renoprotective under comorbid conditions associated with activation of the renin …
(Saxa) is renoprotective under comorbid conditions associated with activation of the renin …
Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle
MFL Alvarez-Canales, SS Salazar-Lopez… - Scientific Reports, 2021 - nature.com
The goal of the study was to evaluate the effect of adding linagliptin to metformin and
lifestyle on glucose levels and pancreatic β-cell function in patients with persistent impaired …
lifestyle on glucose levels and pancreatic β-cell function in patients with persistent impaired …
Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures
Background and aim Cardiovascular diseases (CVDs) are globally the leading cause of
death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 …
death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 …